Medications

FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis

South San Francisco, CA — December 14, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for Ocrevus® (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have […]

Health Problems

Serum biomarker linked to brain atrophy in multiple sclerosis

(HealthDay)—Serum neurofilament light chain (sNFL) levels are significantly associated with clinical and neuroimaging outcomes in multiple sclerosis (MS), according to a study published online Aug. 12 in JAMA Neurology. Ester Cantó, Ph.D., from the University of California in San Francisco, and colleagues conducted a prospective cohort study involving 607 patients with MS to examine the […]